Kate Smallman
YOU?
Author Swipe
View article: Diabetes treatment satisfaction among a multi-ethnic Aotearoa New Zealand population with uncontrolled type 2 diabetes mellitus
Diabetes treatment satisfaction among a multi-ethnic Aotearoa New Zealand population with uncontrolled type 2 diabetes mellitus Open
aims: To assess whether diabetes treatment satisfaction differs by ethnicity among participants with insufficient glycaemic control of type 2 diabetes mellitus in a clinical trial involving additional oral diabetes medications. Patient sat…
View article: Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial
Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial Open
Background Understanding which group of patients with type 2 diabetes will have the most glucose lowering response to certain medications (which target different aspects of glucose metabolism) is the first step in precision medicine. Aims …
View article: Randomised cross-over trial of vildagliptin and pioglitazone as add-on therapy in patients with type 2 diabetes: predicting Which One is Right Here (WORTH) study protocol
Randomised cross-over trial of vildagliptin and pioglitazone as add-on therapy in patients with type 2 diabetes: predicting Which One is Right Here (WORTH) study protocol Open
Introduction There is emerging evidence for stratified glucose-lowering responses to certain oral medications for type 2 diabetes (T2D) by individual characteristics. The objective of this study was to test whether glycaemic response to re…
View article: An Evaluation of Weight Loss Challenges in the Workplace
An Evaluation of Weight Loss Challenges in the Workplace Open
Background: An evaluation [...]
View article: Access to diabetes drugs in New Zealand is inadequate.
Access to diabetes drugs in New Zealand is inadequate. Open
New Zealand is well behind the rest of the developed world in access to funded drugs for managing type 2 diabetes. Over the last 12 years three new classes of glucose-lowering drugs have come through clinical trials to market. The principa…